Clinical Trials: Fabry Disease

Phoenix : AKDHC

A Multi-center, Open-Label, Randomized study evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients with Fabry Disease.

Coral Springs :

A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta

Atlanta : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Cambridge : Participation in this study is not limited to this facility; facilities not yet active may enroll upon identification of a patient

A Study of the Effects of Fabrazyme (Agalsidase Beta) on Mother's Lactation and on the Growth, Development and Immunologic Response of Their Infants

Cambridge : Registry participation is worldwide and not limited to this facility; facilities not yet active may enroll upon identification of a patient.

Fabry Disease Registry

Minneapolis : University of Minnesota, Fariview

Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease

New York : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Columbus : Eye and Ear Institute

Establishment of Biomarkers for Fabry Disease

Pittsburgh : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Dallas : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Seattle : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Parkville : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Graz : Universitätsklinikum für Neurologie

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Porto Alegre : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Montreal : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Zagreb : Department of Neurology, University Hospital Sestre Milosrdnice

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Copenhagen : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Garches : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Lyon : Hopital Neurologique de Lyon, Service d'urgences Neurovasculaires

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Tblisi : Department of Neurology, S. Khechinashvili University clinic of Tbilisi state medical university

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Bayreuth : Department of Neurology, Klinikum Hohe Warte

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Berlin : Charite Campus Benjamin Franklin, Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Celle : Department of Neurology, Allgemeines Krankenhaus Celle

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Chemnitz : Department of Neurology, Klinikum Chemnitz gGmbH

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Dresden : Department of Neurology, Universitaetsklinikum Carl Gustav Carus

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

View More »

Duesseldorf : Heinrich-Heine-University Duesseldorf, Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Giessen : University of Giessen-Marburg Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Hamburg : Department of Neurology, Universitaetsklinikum Hamburg-Eppendorf

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Jena : Department of Neurology, Universitaetsklinikum Jena

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Leipzig : Department of Neurology, Universitaetsklinikum Leipzig

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Mainz : Universitätsklinikum Mainz, Zentrum für Kinder- und Jugendmedizin

Home Therapy With Replagal in Fabry Disease

Mainz : University of Mainz

Sophisticated Assessment of Disease Burden in Patients With Fabry Disease

Mühlhausen / Thürigen : Dept. of Neurology, Ökumenisches Hainich Klinikum gGmbH

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

München : Ludwig-Maximilians-University of Munich, Klinikum München-Großhadern, Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Tuebingen : Department of Neurology, University Tuebingen

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Ulm : University of Ulm, Department of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Roma : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Songpa-gu : Asan Medical Center

Evaluate the Safety and Exploratory Efficacy of GC1119

Warsaw : Institute of Psychiatry and Neurology, Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Lisboa : Centro Hospitalar de Lisboa Central, Servico de Neurologia

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Zaragoza : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat

London : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Salford : GSK Investigational Site

Open-Label Phase 3 Long-Term Safety Study of Migalastat